Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:LTRN OTCMKTS:LTUS NASDAQ:OBSV NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$20.64+0.4%$21.88$7.75▼$27.17$158.27M0.6848,967 shs24,269 shsLTRNLantern Pharma$4.06-1.0%$4.25$2.55▼$6.12$43.85M1.47138,134 shs105,180 shsLTUSLotus Pharmaceuticals$0.01-12.3%$0.01$0.00▼$0.01$15.07M-2.3450,628 shs500 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs16,030 shsOVIDOvid Therapeutics$1.20+4.8%$0.83$0.24▼$1.47$84.98M0.351.03 million shs413,105 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-3.02%-11.23%-19.22%+19.89%+11.99%LTRNLantern Pharma+7.61%+1.23%-10.28%+28.93%+9.04%LTUSLotus Pharmaceuticals0.00%+96.97%-19.05%-9.72%+71.05%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$20.64+0.4%$21.88$7.75▼$27.17$158.27M0.6848,967 shs24,269 shsLTRNLantern Pharma$4.06-1.0%$4.25$2.55▼$6.12$43.85M1.47138,134 shs105,180 shsLTUSLotus Pharmaceuticals$0.01-12.3%$0.01$0.00▼$0.01$15.07M-2.3450,628 shs500 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs16,030 shsOVIDOvid Therapeutics$1.20+4.8%$0.83$0.24▼$1.47$84.98M0.351.03 million shs413,105 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-3.02%-11.23%-19.22%+19.89%+11.99%LTRNLantern Pharma+7.61%+1.23%-10.28%+28.93%+9.04%LTUSLotus Pharmaceuticals0.00%+96.97%-19.05%-9.72%+71.05%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.75Moderate Buy$41.3397.81% UpsideLTRNLantern Pharma 3.00Buy$25.00503.86% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/AOVIDOvid Therapeutics 3.17Buy$3.10163.83% UpsideCurrent Analyst Ratings BreakdownLatest OBSV, LTRN, OVID, ASMB, and LTUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ASMBAssembly BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $39.008/19/2025ASMBAssembly BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/18/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M5.62N/AN/A$5.25 per share3.98LTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/AOVIDOvid Therapeutics$570K146.59N/AN/A$0.96 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.78N/AN/AN/AN/A-99.89%-81.58%11/6/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AOVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)Latest OBSV, LTRN, OVID, ASMB, and LTUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LTRNLantern Pharma-$0.53-$0.40+$0.13-$0.40N/AN/A8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/6/2025Q2 2025ASMBAssembly Biosciences-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A1.641.64LTRNLantern PharmaN/A3.523.52LTUSLotus PharmaceuticalsN/AN/AN/AOBSVObsEvaN/A0.610.61OVIDOvid Therapeutics0.234.724.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%LTRNLantern Pharma28.62%LTUSLotus PharmaceuticalsN/AOBSVObsEva17.52%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.10%LTRNLantern Pharma8.50%LTUSLotus PharmaceuticalsN/AOBSVObsEva14.40%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.67 million7.28 millionOptionableLTRNLantern Pharma2010.80 million9.88 millionOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableOBSV, LTRN, OVID, ASMB, and LTUS HeadlinesRecent News About These CompaniesOvid Therapeutics Regains Nasdaq ComplianceSeptember 16 at 2:39 PM | msn.comOvid Therapeutics (NASDAQ:OVID) Receives $3.10 Average Price Target from AnalystsSeptember 10, 2025 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ovid TherapeuticsAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Invests $208,000 in Ovid Therapeutics $OVIDAugust 28, 2025 | marketbeat.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 24, 2025 | finance.yahoo.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 23, 2025 | insidermonkey.comOvid Therapeutics (NASDAQ:OVID) Short Interest Up 54.8% in JulyAugust 22, 2025 | marketbeat.comSpotlight On 3 Promising Penny Stocks With Over $60M Market CapAugust 20, 2025 | uk.finance.yahoo.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsAugust 19, 2025 | marketbeat.comQ3 EPS Estimates for Ovid Therapeutics Increased by B. RileyAugust 19, 2025 | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for OVIDAugust 19, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSAugust 17, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comOvid Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comOvid Therapeutics Reports Increased Revenue Amid ChallengesAugust 14, 2025 | msn.comOvid Therapeutics Navigates FDA Disruptions and Government ChallengesAugust 14, 2025 | tipranks.comOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy RatingAugust 13, 2025 | tipranks.comOvid Therapeutics initiated with a Buy at Lucid CapitalAugust 13, 2025 | msn.comOvid Therapeutics Transfers Stock to Nasdaq Capital MarketAugust 13, 2025 | msn.comOvid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025OBSV, LTRN, OVID, ASMB, and LTUS Company DescriptionsAssembly Biosciences NASDAQ:ASMB$20.64 +0.09 (+0.41%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Lantern Pharma NASDAQ:LTRN$4.06 -0.04 (-0.98%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0057 0.00 (-12.31%) As of 10:27 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Ovid Therapeutics NASDAQ:OVID$1.20 +0.06 (+4.82%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
